I
IONS
Ionis Pharmaceuticals
45.28
+1.98+4.57%After Hours: 44.97 -0.31 -0.68%19:55 10/09 EDT
OPEN/PREV CLOSE43.21/43.30
TODAY RANGE43.12-45.72
VOL4.86M
MARKET CAP7.52B
52 WEEK RANGE42.63-86.74
AVG VOL (3M)3.41M
% TURNOVER2.60%
TURNOVER--
P/E (TTM)-13.0419
% RANGE6.00%
EPS(TTM)-3.4719
P/E(FORWARD)-12.6333
P/B17.06
BVPS2.655
DIVIDEND--
P/S7.84
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP7.45B
SHARES OUTSTANDING166.18M
NEXT EARNINGS10/27-11/02
FREE FLOAT164.43M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
TipRanks·2d ago
Wall Street Analysts Are Bullish on Top Healthcare Picks
Simply Wall St·2d ago
Is Ionis Pharmaceuticals (IONS) Stock Fully Valued After A 45% Fall?
Simply Wall St·4d ago
How Investors May Respond To Ionis Stock After Phase 3 Kidney Disease Trial Win
Seeking Alpha·5d ago
Moat Stocks Retreat As Market Breadth Narrows
Simply Wall St·10/03 00:29
Ionis Pharmaceuticals Fell 45% With The Case Still Split
Seeking Alpha·10/01 11:44
These ten healthcare stocks posted the biggest one-month losses
Simply Wall St·09/30 02:18
What Ionis Pharmaceuticals (IONS)'s Phase 3 Wins Mean For Shareholders
Seeking Alpha·09/28 16:04
Alnylam Pharmaceuticals: More Than Meets The Eye After CARDIO-TTRansform
Seeking Alpha·09/28 11:30
Cathie Wood's Ark Invest weekly recap: boosts Meta, Rocket Lab; cuts Tempus AI, CrowdStrike
Simply Wall St·09/27 14:14
Ionis Pharmaceuticals (IONS) Reports Fresh Phase 3 Wins, Is The 49% Discount Justified?
Simply Wall St·09/25 02:27
Ionis Pharmaceuticals (IONS) Posted Two Positive Phase 3 Trial Readouts